Biorestorative shares surge 62.02% intraday after Australia approves ThermoStem patent, bolstering cell-based obesity therapy pipeline.

Biorestorative Therapies (NASDAQ:BRTX) surged 62.02% intraday following the announcement that IP Australia approved its patent for ThermoStem® technology, a cell-based alternative to GLP-1 drugs. The patent, covering non-naturally occurring 3D brown adipose-derived stem cell aggregates, strengthens the company’s global intellectual property portfolio and positions ThermoStem as a potential next-generation therapy for obesity and metabolic disorders. The news highlights BioRestorative’s progress in addressing limitations of GLP-1 drugs, such as tolerability issues and cardiovascular risks, while expanding its competitive moat in regenerative medicine. CEO Lance Alstodt emphasized the significance of securing IP in key markets, underscoring the company’s strategic focus on long-term efficacy and safety advantages over existing therapies. The intraday rally aligns with investor optimism over the patent’s role in advancing the company’s pipeline and market differentiation.